FOSTER CITY, Calif. / Dec 22, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 12, 2026 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About... Read More

Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif. / Dec 22, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex... Read More

Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership Company reinforces commitment to U.S. manufacturing and American jobs FOSTER CITY, Calif. / Dec 19, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing... Read More

FOSTER CITY, Calif. / Dec 18, 2025 / Business Wire / Gilead Sciences, Inc . (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day. Ms. Wettan has held increasingly senior legal leadership roles within Gilead during... Read More

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions FOSTER CITY, Calif. / Dec 15, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses... Read More

Funding Empowers 53 Organizations to Enhance Education, Care and Support Services FOSTER CITY, Calif. / Dec 09, 2025 / Business Wire / Gilead Foundation today announced a commitment of more than $3 million in new grants to help address critical gaps in education, care delivery and support services for people affected by metastatic breast cancer (mBC). Building on more than $21 million in support since 2021, funding... Read More

Benefits Seen Regardless of Eligibility for Previous Standard of Care of High-Dose Chemotherapy and Stem Cell Transplant for Second-Line Treatment SANTA MONICA, Calif. / Dec 07, 2025 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta ® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell... Read More

96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing to Deepen Over Time Observed Safety Profile is Predictable and Manageable to Date; No Delayed Neurotoxicities or Immune Effector Cell-Associated Enterocolitis across Phase 1 and 2 (iMMagine-1) Studies Data from Investigational Agent... Read More

Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High Complete Response Rate and Favorable Safety Trend Novel Construct for Two Investigational Therapies Could Enable Safer, More Effective and Accessible CAR Ts SANTA MONICA, Calif. / Dec 06, 2025 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and... Read More

Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. FOSTER CITY, Calif. / Nov 24, 2025 / Business Wire / Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique... Read More

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc. , a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease. The Series C round was co-led by OrbiMed, ARCH... Read More

Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa FOSTER CITY, Calif. & MBABANE, Eswatini / Nov 18, 2025 / Business Wire / Gilead Sciences, Inc . (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure... Read More

The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions FOSTER CITY, Calif. / Nov 13, 2025 / Business Wire / Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the... Read More

FOSTER CITY, Calif. / Nov 07, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy ® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central... Read More

New Data Exclusive to Livdelzi Highlights its Potential as an Effective and Well-Tolerated Option for PBC Patients Switching from Obeticholic Acid Analysis of Phase 3 ASSURE Study Finds Livdelzi Shows Promising Data on Liver Stiffness in PBC Patients After 3 Years Livdelzi Data in PBC Participants Provide Outcomes for Long-Term Biochemical Response, which Slows Disease Progression and Sustained Reductions in Chronic Itch,... Read More

FOSTER CITY, Calif. / Nov 04, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern Time Jefferies Global Healthcare Conference in London on Wednesday, November 19 at 2:00 PM Greenwich Mean Time Citi’s Global Healthcare Conference on Tuesday, December 2... Read More

Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented Orally New Findings Reinforce Yescarta’s ® Curative Potential as Second-Line Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma Next-Generation CAR T-cell Therapies Suggest High Response Rates and Encouraging Durability in B-Cell Malignancies FOSTER CITY, Calif. / Nov 03, 2025 / Business... Read More

FOSTER CITY, Calif. / Oct 31, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo ® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure... Read More

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sales Increased 6% Year-Over-Year to $3.7 billion FOSTER CITY, Calif. / Oct 30, 2025 / Business Wire / Gilead Sciences, Inc . (Nasdaq: GILD) announced today its third quarter 2025 results of operations. “We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and... Read More

Late-Breaking Real-World Experience of People Switching from Obeticholic Acid to Livdelzi ® to be Presented at The Liver Meeting ® 2025 New Three-Year Interim Data Demonstrates Livdelzi ® May Help Stabilize or Improve Liver Health in PBC Patients FOSTER CITY, Calif. / Oct 23, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people... Read More

LYVDELZI is the Only Medicine to Demonstrate Statistically Significant and Durable Improvements in Both Pruritus and Markers of Cholestasis Related to the Risk of Disease Progression in a Phase 3 Trial LYVDELZI Expands Gilead's Long-Standing Commitment to People Living with Liver Disease MISSISSAUGA, ON , Oct. 21, 2025 /CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI... Read More

Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations New Data Show Higher Treatment Satisfaction After Switching from IM CAB+RPV to Biktarvy ® New Research Reaffirms Veklury ® in High-Risk COVID-19 Populations and Obeldesivir in Emerging Pathogens FOSTER CITY, Calif. / Oct 19, 2025 / Business Wire / Gilead Sciences, Inc.... Read More

Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First and Only ADC to be a Backbone Standard of Care for All First-Line Metastatic TNBC Patients Regardless of PD-L1 Status FOSTER CITY, Calif. / Oct 19, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data... Read More

New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Recruitment Strategies for PURPOSE 5 Five-Year BICSTaR Results Offer Insights into Long-Term Treatment with Biktarvy ® , Helping Inform the Future of Coordinated, Person-Centered HIV Care Latest Results on Novel Long-Acting Combination Regimens, Including Once-Weekly and Twice-Yearly Treatment Options... Read More

Late-breaking Phase 3 ASCENT-03 Study Results Highlight Potential for Trodelvy ® to Redefine First-Line Metastatic Triple-Negative Breast Cancer Treatment New EDGE-Gastric Overall Survival Results, for Anti-TIGIT Domvanalimab plus Anti-PD-1 Zimberelimab and Chemotherapy also to be Presented FOSTER CITY, Calif. / Oct 13, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate... Read More

FOSTER CITY, Calif. / Oct 09, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business update. A live webcast will be... Read More

Combined Funding Strengthens Bay Area Community with STEM Curriculum, Building Scientific, Technology and Mathematics Literacy FOSTER CITY, Calif. / Sep 25, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond.... Read More

PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access FOSTER CITY, Calif. / Sep 04, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief... Read More

Glo bal Initiative Seeks to Empower Individuals Navigating HIV Care Journey FOSTER CITY, Calif. / Sep 04, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™ , a new campaign that spotlights the multifaceted experiences of people living with HIV globally. The timing of the campaign launch coincides with the convening of the 2025 United States Conference on HIV/AIDS (USCHA)... Read More

New Bay Area Building Marks Significant Progress as Part of $32 Billion U.S. Investment Projected to Create $43 Billion in Economic Value FOSTER CITY, Calif. / Sep 03, 2025 / Business Wire / Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks... Read More

Yeytuo ® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protection Accelerated EC Decision Comes After U.S. FDA Approval in June FOSTER CITY, Calif. / Aug 26, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo ® (lenacapavir)—the company’s twice-yearly injectable HIV-1... Read More

SANTA MONICA, Calif. & PHILADELPHIA / Aug 21, 2025 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite's expertise in cell therapy by incorporating Interius's integrating in vivo platform. This... Read More

FOSTER CITY, Calif. / Aug 20, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM Eastern Time Wells Fargo Healthcare Conference on Thursday, September 4 at 11:00 AM Eastern Time Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 9... Read More

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion FOSTER CITY, Calif. / Aug 07, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first twice-yearly HIV... Read More

If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV PrEP Option in the European Union Positive Opinion Also Received for EMA’s EU-M4all Procedure, Designed to Facilitate Availability in Low- and Lower-Middle-Income Countries FOSTER CITY, Calif. / Jul 25, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European... Read More

FOSTER CITY, Calif. / Jul 24, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2025 financial results and guidance will be released on Thursday, August 7, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2025 financial results and provide a business update. A live webcast will be... Read More

New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo ® ) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, Adolescents and Young People Data Also Showed Twice-Yearly Injectable PrEP was Preferred vs. Daily Oral Medication Among PURPOSE Trial Participants Gilead’s Research Presentations and Community Events at IAS Reflect Commitment to... Read More

Strategic Partnership Agreement is Part of Gilead’s Commitment to Provide Lenacapavir at No Profit in High-Incidence, Resource-Limited Countries Until Licensed Generics Can Fully Meet Demand FOSTER CITY, Calif. / Jul 09, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply... Read More

FOSTER CITY, Calif. & WATERTOWN, Mass. / Jun 25, 2025 / Business Wire / Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential... Read More

Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo Yeztugo, Nearly 20 Years in the Making, Represents a Major Breakthrough in the Fight Against HIV FOSTER CITY, Calif. / Jun 18, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo ®... Read More

Long-Term Analysis Shows Similar Safety and Effectiveness Outcomes in Outpatient vs. Inpatient Setting with Positive Impact for Healthcare Systems SANTA MONICA, Calif. / Jun 01, 2025 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta ® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)... Read More

First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC Early Trend in Improvement in Overall Survival Observed FOSTER CITY, Calif. / May 31, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy ® (sacituzumab govitecan-hziy) plus Keytruda ® (pembrolizumab) reduced the risk of disease progression... Read More

Second Positive Phase 3 Trial in First-line Metastatic TNBC Where Trodelvy Has Demonstrated a Clinically Meaningful Benefit Versus Standard of Care Chemotherapy Trodelvy Has the Potential to Be the Backbone of Treatment and the First Antibody-Drug Conjugate for All Patients Across First-line Metastatic TNBC FOSTER CITY, Calif. / May 23, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive... Read More

Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy ® plus Keytruda ® in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer FOSTER CITY, Calif. & SANTA MONICA, Calif. / May 15, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting May 30... Read More

90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment FOSTER CITY, Calif. / May 07, 2025 / Business Wire / Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis... Read More

– 60% of Participants with Prior Fibrate or Obeticholic Acid Treatment Achieve Biochemical Response with Livdelzi – – New Evidence Supports Livdelzi Delivers Clinically and Statistically Significant Improvements in Pruritus – FOSTER CITY, Calif. / May 07, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi ® (seladelpar), known as Lyvdelzi... Read More

FOSTER CITY, Calif. / Apr 29, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 29... Read More

New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in people with primary biliary cholangitis (PBC) Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus (HDV)... Read More

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion FOSTER CITY, Calif. / Apr 24, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. “Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said... Read More

The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously Untreated PD-L1+ (CPS ≥10) mTNBC FOSTER CITY, Calif. / Apr 21, 2025 / Business Wire / Gilead Sciences, Inc.... Read More

FOSTER CITY, Calif. / Apr 10, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2025 financial results and provide a business update. A live webcast will be... Read More

Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy Designation Late-Breaker Oral Presentation of Phase 2 Results from the First HIV Cure Clinical Trial Conducted in South Africa FOSTER... Read More

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 Also at CROI: New PURPOSE 1 Data Showcasing Preference for Twice-Yearly Lenacapavir vs. Once-Daily Orals and In-Depth Look at Adolescent Pharmacokinetic, Safety and Efficacy Data FOSTER CITY, Calif. / Mar 11, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today presented the... Read More

One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries Both Applications Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline Based on Potential Public Health Interest in Lenacapavir for HIV Prevention EMA Validation Follows Acceptance of U.S. Applications by FDA Under Priority Review FOSTER CITY, Calif. / Feb 24,... Read More

Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area First and Only Treatment That Achieved Statistically Significant Improvements Across Biochemical Response, Alkaline Phosphatase Normalization, and Pruritus Versus Placebo FOSTER CITY, Calif. / Feb 20, 2025 / Business Wire / Gilead Sciences, Inc . (Nasdaq: GILD) today announced that... Read More

FOSTER CITY, Calif. / Feb 19, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 11 at 10:40 AM Eastern Time The live webcasts can be accessed at the company’s investors page at... Read More

If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV Prevention Choice FDA to Review Applications Under Priority Review, with a PDUFA Date of June 19, 2025 Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline FOSTER CITY, Calif. / Feb 18, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq:... Read More

FOSTER CITY, Calif. / Feb 11, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s quarterly cash dividend, beginning in the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. The dividend is payable on March 28, 2025, to stockholders of record at the close of... Read More

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024 Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2024 Oncology Sales Increased 12% Year-Over-Year to $3.3 billion for Full Year 2024 FOSTER CITY, Calif. / Feb 11, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year... Read More

Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizan t (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening... Read More

FOSTER CITY, Calif. / Jan 28, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2024 financial results and provide a... Read More

Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in... Read More

FOSTER CITY, Calif. / Dec 20, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About... Read More

FOSTER CITY, Calif. / Dec 17, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy ® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The Breakthrough Therapy... Read More

Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration FOSTER CITY, Calif. & LOS ANGELES / Dec 17, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic... Read More

Recommendation Based on the RESPONSE Study Which Demonstrated ALP Normalization in 25% of Participants at 12 Months and Statistically Significant Reduction of Pruritus Versus Placebo If Approved by the European Commission, Seladelpar Would Provide an Important Treatment Option for People Living with the Rare Liver Disease in the EU FOSTER CITY, Calif. / Dec 13, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD)... Read More

FOSTER CITY, Calif. / Dec 12, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive... Read More

ZUMA-5 Analysis Shows Median Progression-Free Survival of 62.2 Months and Median Duration of Response of 60.4 Months After Median Follow-Up of More Than Five Years Over Half of Patients Alive at Time of Analysis, with No Need for Subsequent Therapy and Rare Instances of Late Disease Progression, Indicating Curative Potential SANTA MONICA, Calif. / Dec 09, 2024 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today... Read More

Only CAR T to Demonstrate Prolonged Overall Survival After Five Years Follow-Up in Relapsed/Refractory Mantle Cell Lymphoma ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients Real-World Evidence Analysis Shows High Effectiveness and Safety Profile Consistent with ZUMA-3 in Broader Relapsed/Refractory B-Cell Precursor Acute... Read More

Largest Real-World Evidence (RWE) Analysis of Yescarta in Second-Line Shows 71% Overall Survival Rate, Consistent with Pivotal ZUMA-7 Study, in Broader Patient Population with Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) RWE Shows Decreasing Trend Over Time of Cytokine Release Syndrome and Related Adverse Events After Yescarta Treatment in Third-Line Plus Setting Findings from ALYCANTE Study Show Stable Long-Term... Read More

Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise Agreement Provides Gilead with Exclusive Option to License the Resulting ADC Program for Further Development FOSTER CITY, Calif & MUNICH / Dec 03, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they... Read More

FOSTER CITY, Calif. / Nov 27, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine ( NEJM ) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. The study found that... Read More

New Findings Demonstrate 81% of Participants Achieve Durable Biochemical Response by Month 30 with Livdelzi Nearly Half of Participants with Primary Biliary Cholangitis (PBC) Achieve Alkaline Phosphatase (ALP) Normalization with Livdelzi Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with Moderate to Severe Itch FOSTER CITY, Calif. / Nov 15, 2024 / Business... Read More

FOSTER CITY, Calif. / Nov 13, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1... Read More

Newly Presented Results, to be Published in The New England Journal of Medicine, Include Adherence and Pharmacokinetics Data; Data Underscore High Efficacy and Safety Profile of Lenacapavir Among Broad and Geographically Diverse Range of Individuals FDA Recently Granted Breakthrough Therapy Designation for Lenacapavir for PrEP; Gilead to Begin Regulatory Filings by End of 2024 Gilead Spearheading Lenacapavir Access... Read More

Four-Year Outcomes from the BICSTaR Study Further Demonstrate the Long-Term Efficacy and Safety Profile of Biktarvy ® , Providing Insights for HIV Clinical Care New Data on HIV Treatment Patterns Reinforce the High Barrier to Resistance of Biktarvy Investigational Regimens with Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequencies Across Administration Methods Aim to Expand Options, Help Address Unmet Needs in HIV... Read More

FOSTER CITY, Calif. / Nov 08, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare Conference on Wednesday, November 20 at 9:30 AM Greenwich Mean Time Piper Sandler Annual Healthcare Conference on Tuesday, December 3 at 11:00 AM Eastern Time Annual Evercore ISI HealthCONx Conference on Wednesday,... Read More

Full Results From PURPOSE 2 Study Exploring Lenacapavir as a Potential Twice-Yearly HIV Prevention Option Among a Broad and Geographically Diverse Range of Cisgender Men and Gender-Diverse People Four-Year Outcomes From Real-World BICSTaR Study Further Demonstrate the Consistent Efficacy and Safety Profile of Biktarvy, Providing Insights for HIV Clinical Care Late-Breaking Oral Presentation From Phase 2 Study Evaluating an... Read More

Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million FOSTER CITY, Calif. / Nov 06, 2024 / Business Wire / Gilead Sciences, Inc . (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest of the year to date, with 7%... Read More

Durability of Response and Continued Manageable Safety Profile for the Phase 1 and iMMagine-1 Studies with Anito-cel in Patients with Relapsed/Refractory Multiple Myeloma to be Presented by Partner Arcellx; Follows Progress with First Patient Dosed in Phase 3 iMMagine-3 Study Survival Rate for Yescarta ® Supported by Largest Real-World Analysis of CAR T for Second-Line Therapy in Patients with Relapsed/Refractory Large... Read More

Expanded agreement includes development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs FOSTER CITY, CA / ACCESSWIRE / October 31, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the expansion of a previous agreement with Gilead Sciences, Inc.... Read More

Key Insights from Viral Hepatitis, PBC, and MASH/Fibrosis Studies Highlight Gilead's Ongoing Commitment to Advancing Life-Changing Liver Disease Research FOSTER CITY, Calif. / Oct 22, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting ® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego,... Read More

Novel Investigational Combination Regimen is Advancing to Phase 3 and has the Potential to Become the First Weekly Oral HIV Treatment FOSTER CITY, Calif., & RAHWAY, N.J. / Oct 19, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a Phase 2 clinical study evaluating the investigational combination of... Read More

FOSTER CITY, Calif. / Oct 09, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2024 financial results and provide a business update. A live webcast will... Read More

Latest Outcomes From HIV Prevention and Treatment Clinical Research, Including Data From Pivotal Phase 3 PURPOSE 1 & 2 Trials Real World Evidence in COVID-19 Reinforce Veklury (remdesivir) as the Antiviral Standard of Care for the Treatment of People Hospitalized for COVID-19 Investigational Obeldesivir Safety and Tolerability Data From BIRCH and OAKTREE Trials Support Continued Evaluation as a Potential Treatment Option for... Read More

Efficacy and Safety Data Demonstrated 96% Reduction in HIV Infections with Lenacapavir Compared to Background HIV Incidence Among a Geographically Diverse Population of Cisgender Men and Gender-Diverse People Gilead to Begin Regulatory Filings for Lenacapavir for PrEP by End of 2024 Gilead Recently Announced Voluntary Licensing Partners to Expand Future Access in High-Incidence, Resource-Limited Countries FOSTER CITY, Calif.... Read More

Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India , Oct. 2, 2024 /PRNewswire/ -- Hetero , India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq:... Read More

License for Companies to Manufacture and Supply High-Quality, Low-Cost Versions of Lenacapavir for 120 Primarily Low- and Lower-Middle Income Countries Gilead Plans to Price Product at No Profit to the Company and Supply Lenacapavir Until Generic Manufacturers Fully Support Demand Agreements Also Cover Lenacapavir for HIV Treatment in Heavily Treatment-Experienced Adults with Multi-Drug Resistant HIV FOSTER CITY, Calif. /... Read More

99.9% of Participants Did Not Acquire HIV Infection in the Lenacapavir Group, with 2 Incident Cases Among 2,180 Participants PURPOSE 2 Trial Results for Cisgender Men and Gender-Diverse People Add to the Body of Evidence for the Investigational Use of Lenacapavir for HIV Prevention Gilead Stopped the Blinded Phase of the Trial at Interim Analysis and Will Offer Open-Label Lenacapavir to All Participants FOSTER CITY, Calif. /... Read More

Gilead and Genesis Will Leverage the GEMS AI Platform to Generate and Jointly Optimize Molecules Against Selected Targets Gilead Receives Exclusive Rights to Develop and Commercialize Products from the Collaboration FOSTER CITY, Calif. & BURLINGAME, Calif. / Sep 10, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic... Read More

Data Span Multiple Types of Lung Cancer and Lines of Therapy FOSTER CITY, Calif. / Sep 05, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be... Read More

FOSTER CITY, Calif. / Aug 21, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4 at 11:00 AM Eastern Time Morgan Stanley Annual Global Healthcare Conference on Thursday, September 5 at 12:20 PM Eastern Time Baird Global Healthcare Conference on Tuesday, September 10... Read More

First and Only Treatment to Demonstrate Statistically Significant Reductions Across Key Biomarkers, ALP Normalization and Pruritus Versus Placebo Livdelzi Expands Gilead’s Long-Standing Commitment to People Living with Liver Disease FOSTER CITY, Calif. / Aug 14, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today... Read More

Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841 million FOSTER CITY, Calif. / Aug 08, 2024 / Business Wire / Gilead Sciences, Inc . (Nasdaq: GILD) announced today its second quarter 2024 results of operations. “Gilead has had another strong quarter with 6% year-over-year growth in our... Read More

FOSTER CITY, Calif. / Jul 25, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2024 financial results and provide a business update. A live webcast will... Read More

New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequencies Across Administration Methods Aim to Expand Options, Advance Public Health and Help Address Unmet Needs in HIV Treatment FOSTER CITY, Calif. / Jul 25, 2024 / Business Wire / Gilead... Read More

PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address Critical Gaps in Uptake and Adherence for Individuals Who Need or Want PrEP Gilead Commits to Prioritizing Swift Access and Enabling Efficient Paths for Regulatory Approval of Lenacapavir... Read More

RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Impacted by the Conflict in Ukraine with HIV Prevention and Care Services FOSTER CITY, Calif. /... Read More

FOSTER CITY, Calif. / Jul 17, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this transition over the next several months. “On behalf of everyone at Gilead, I want... Read More

- Late-Breaking Full Results from HIV Prevention Research of Twice-Yearly Injectable Lenacapavir - - Progress and Person-Centered Approaches Across HIV Treatment, Cure Research and Development Programs - - Key Initiatives Demonstrate Commitment to Collaboration to Help End the HIV Epidemic Worldwide - FOSTER CITY, Calif. / Jul 16, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced its program for the... Read More

First Phase 3 HIV Prevention Trial Ever to Show Zero Infections Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants FOSTER CITY, Calif. / Jun 20, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1... Read More

Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment Data Builds on Previous Evidence on the Association Between Timely Infusion and Patient Outcomes Preliminary Results Supporting Safety and Feasibility of Outpatient Administration of Yescarta and Tecartus ® to be Presented SANTA MONICA,... Read More

Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg in Combination with Pegylated Interferon Alfa-2a as Finite Therapy for People with Chronic Hepatitis Delta Data Published in NEJM Demonstrate 46% of Patients Taking Bulevirtide 10 mg with PegIFN Achieved Post-Treatment Undetectable HDV RNA at Week 24 Data Presented at EASL Demonstrate Consistent Study Findings of Undetectable HDV RNA... Read More

Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent with One-year Interim Analysis Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Participants with Moderate to Severe Symptoms Subset Analysis of Participants with Compensated Cirrhosis Demonstrated Clinically Meaningful Improvements in Markers of Cholestasis and Liver Injury... Read More

After More Than Four Years of Follow-up in the Pivotal ZUMA-3 Study, Median Overall Survival (OS) was 26 Months and the OS Rate was 40% at 48 Months Survival Benefit was Seen Regardless of Age, Prior Treatment or Subsequent Allogeneic Stem Cell Transplant Status Data Being Presented at the 2024 American Society of Clinical Oncology Annual Meeting SANTA MONICA, Calif. / Jun 03, 2024 / Business Wire / Kite, a Gilead Company... Read More

At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed Findings Also Suggest Efficacy Trend with Median Progression-Free Survival and Durability of Response of More Than a Year Data Presented Orally at the 2024 American Society of Clinical Oncology Annual Meeting SANTA MONICA, Calif. / Jun 03, 2024 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), announced data... Read More

In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab Significantly Reduced the Risk of Death by 63% and Risk of Disease Progression by 73% Compared to Regorafenib in a Phase 1b/2 Trial Results will be Presented Today During an Oral Session at the ASCO Annual Meeting FOSTER CITY, Calif. & HAYWARD, Calif. / Jun 02, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD)... Read More

Data Support the Ongoing Phase 3 STAR-221 Study of Domvanalimab Plus Zimberelimab and Chemotherapy, Potentially the First Anti-TIGIT Combination to Market for These Cancers Results will be Presented Today During an Oral Session at the ASCO Annual Meeting FOSTER CITY, Calif. & HAYWARD, Calif. / Jun 01, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced... Read More

Simultaneously Published by the Journal of Clinical Oncology FOSTER CITY, Calif. / May 31, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also published simultaneously in... Read More

FOSTER CITY, Calif. / May 30, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy ® (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have previously received... Read More

Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease FOSTER CITY, Calif. / May 22, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:... Read More

70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms Positive Interim Results are Highly Consistent with Results from the Phase 3 RESPONSE Study of Seladelpar FOSTER CITY, Calif. / May 18, 2024 / Business Wire / Gilead... Read More

Analysis Comparing Real-World and Clinical Trial Data Show Yescarta ® Has Higher Manufacturing Success Rates and Improved T-Cell Performance, Respectively, in Second-Line vs. Third-Line+ Treatment of Large B-cell Lymphoma Encore Oral Presentation from the Phase 1 Study of Anitocabtagene autoleucel (anito-cel) in Relapsed/Refractory Multiple Myeloma (R/R MM); Trial Design for Phase 3 iMMagine-3 Pivotal Study for R/R MM to be... Read More

The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete Remain on track to present preliminary data from the iMMagine-1 trial by end of the year REDWOOD CITY,... Read More

Non-Small Cell Lung Cancer Development Program Data to be Presented, Including the Phase 3 EVOKE-01 Study Updated Results from Phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus A nti-PD-1 Zimberelimab, to be Presented Pilot Study Results of Yescarta ® in Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas, an Area of Unmet Clinical Need, to be Presented Orally FOSTER CITY, Calif. &... Read More

FOSTER CITY, Calif. / Apr 30, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 14 at 11:20am Pacific Time RBCCM Global Healthcare Conference on Wednesday, May 15 at 10:30am Eastern Time Jefferies Global Healthcare Conference on Wednesday, June 5 at 11:00am Eastern Time... Read More

Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy and for Those Trying to Conceive FOSTER CITY, Calif. / Apr 26, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA)... Read More

Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) FOSTER CITY, Calif. / Apr 25, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024... Read More

FOSTER CITY, Calif. / Apr 08, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2024 financial results and provide a business update. A live webcast will be... Read More

Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older FOSTER CITY, Calif. / Mar 28, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy ® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for... Read More

Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases FOSTER CITY, Calif. / Mar 22, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead... Read More

LAFAYETTE, Colo. / Mar 18, 2024 / Business Wire / The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. In this first round, CDA... Read More

FOSTER CITY, Calif. / Mar 11, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024. On February 22, 2024, Gilead and CymaBay filed the Premerger Notification and Report Forms required... Read More

New Data Evaluating the Efficacy and Safety Profile of Biktarvy for the Treatment of People with HIV and Hepatitis B or Tuberculosis will be Presented Retrospective Analysis Evaluating HIV Resistance-Associated Mutations Reinforces Importance of Treatment Selection in HIV Management FOSTER CITY, Calif. / Mar 06, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three studies evaluating... Read More

Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People with HIV Novel Investigational Combination Regimen has the Potential to be the First Oral Weekly HIV Treatment, Helping to Address Unmet Needs FOSTER CITY, Calif., & RAHWAY, N.J. / Mar 06, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD... Read More

Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration FOSTER CITY, Calif. / Mar 06, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on... Read More

Veklury Was Associated With a Lower Risk of Developing Long-COVID in One Analysis Veklury Was Associated With a Reduced Risk of Mortality Among People Who Are Immunocompromised in a Separate Analysis FOSTER CITY, Calif. / Mar 05, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and... Read More

New Positive Clinical Data Demonstrate Momentum on Investigational Once-Daily, Once-Weekly and Twice-Yearly Dosing Strategies Key Findings from Studies Evaluating Potential Future Long-Acting Combination Regimens Affirm Commitment to Continuous Biomedical Innovation FOSTER CITY, Calif. / Mar 05, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth... Read More

19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead’s Setting the P.A.C.E. Initiative FOSTER CITY, Calif. / Feb 27, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. These grants are a part of Gilead’s... Read More

Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically Suppressed with M184V/I Resistance M184V/I One of the Most Common Forms of Resistance Among People with HIV Biktarvy Is a Long-Term Treatment Option with a High Barrier to Resistance for a Broad Range of Individuals FOSTER CITY, Calif. / Feb 26, 2024 / Business Wire / Gilead... Read More

Key Findings from HIV Treatment Research Studies Evaluating Biktarvy ® and Investigational Long-Acting Combination Regimens Affirm Commitment to Continuous Biomedical Innovation Latest Real-World Evidence Analyses Evaluate Impact of Veklury ® on Mortality and Long-COVID New Data Evaluating the Safety and Efficacy of Hepcludex ® in People with HIV/HBV/HDV Coinfection to Be Presented FOSTER CITY, Calif. / Feb 26, 2024 /... Read More

FOSTER CITY, Calif. / Feb 20, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 5 at 12:50pm Eastern Time Leerink Partners Global Biopharma Conference on Tuesday, March 12 at 10:00am Eastern Time Barclays Annual Global Healthcare Conference on Wednesday, March 13 at... Read More

Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC Acquisition Expands Gilead’s Long-Standing Commitment to Patients with Liver Diseases FOSTER CITY, Calif. & NEWARK, Calif. / Feb 12, 2024 / Business Wire /... Read More

Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry FOSTER CITY, Calif. / Feb 09, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and... Read More

FOSTER CITY, Calif. / Feb 06, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of... Read More

Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased Year-Over-Year by 37% for Full Year 2023 FOSTER CITY, Calif. / Feb 06, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of... Read More

FOSTER CITY, Calif. / Feb 01, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of... Read More

New Median Turnaround Time from Leukapheresis to Product Release in U.S. Anticipated to be Reduced from 16 Days to 14 Days Continues to Support Kite’s Industry-Leading Overall Turnaround Time and Reliability Time to Treatment is a Critical Factor for CAR T-cell Therapy Patients SANTA MONICA, Calif. / Jan 30, 2024 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug... Read More

Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program Additional Equity Investment of $320M, Raising Gilead’s Ownership Stake in Arcus to 33% Amendment Provides Gilead with One Additional Seat on the Arcus Board FOSTER CITY, Calif. & HAYWARD, Calif. / Jan 29, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE:... Read More

FOSTER CITY, Calif. / Jan 23, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2023 financial results and provide a business... Read More

FOSTER CITY, Calif. / Jan 22, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy ® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after... Read More

Yescarta is the First and Only Treatment in Nearly 30 Years to Demonstrate Superior Overall Survival for Patients with Relapsed/Refractory Large B-cell Lymphoma Versus Standard of Care as Second-Line Treatment With Curative Intent* SANTA MONICA, Calif. / Dec 21, 2023 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for... Read More

FOSTER CITY, Calif. / Dec 21, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 8, 2024 beginning at 10:30 a.m. Pacific Time The live webcast can be accessed at the company’s investors page at investors.gilead.com . The replay will be available for at least 30 days... Read More

Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone Payment with a Total Deal Value of up to $848 Million FOSTER CITY, Calif. & HOLON, Israel / Dec 19, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced... Read More

ZUMA-1 Post-Hoc Analysis Shows Five-Year Lymphoma-Related Event-Free Survival in a Substantial Proportion of Patients with Refractory Large B-cell Lymphoma Four-Year Follow-up from ZUMA-5 Demonstrates Continued Durable Response and Long-Term Survival in Patients with Relapsed/Refractory Follicular Lymphoma ZUMA-7 Overall Survival Subgroup Analysis in Patients Aged 65+ Shows that Age Alone is not a Barrier to Receiving CAR T... Read More

At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-Term Response in Adult Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Real-World Evidence (RWE) Shows Effectiveness in Adult R/R MCL with a Complete Response Rate of 81% and 84% for High-Risk Features (Patients with TP53 /17p Deletion) RWE Also Shows a Complete Remission/CRi Rate of 76%... Read More

First Ever Prospective Phase 2 Study to Evaluate CAR T-Cell Therapy as First-Line Therapy Reads Out Three-Year Follow-Up Analysis At Median Follow-Up of 40.9 Months, Patients Treated with Yescarta ® Experienced an 86% Complete Response Rate and the Three-Year Estimate for Overall Survival was 81% High-Risk Large B-Cell Lymphoma (LBCL) Patients Typically Face Poor Prognoses with Conventional Treatment, with Median Overall... Read More

Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead’s Ongoing Commitment to Corporate Responsibility DJSI World Highlights the Most Sustainable Companies Around the World Based on Corporate Sustainability Assessment FOSTER CITY, Calif. / Dec 11, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the... Read More

FOSTER CITY, Calif. / Nov 30, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy ® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Data featured in eight presentations include an... Read More

The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment SANTA MONICA, Calif. & REDWOOD CITY, Calif. / Nov 15, 2023 / Business Wire / Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ:... Read More

FOSTER CITY, Calif. / Nov 08, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare Conference on Wednesday, November 15 at 9:00am Greenwich Mean Time Evercore ISI HealthCONx Conference on Tuesday, November 28 at 1:20pm Eastern Time Piper Sandler Healthcare Conference on Wednesday, November 29 at... Read More

Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales Increased 33% Year-Over-Year to $769 million FOSTER CITY, Calif. / Nov 07, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023. “Gilead has now delivered two years of consistent growth in our base... Read More

Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers Detailed results will be presented on November 7 at 12pm PT / 3pm ET during the ASCO Monthly Plenary Series FOSTER CITY,... Read More

Three Oral Presentations and 30 Posters Across HBV, HCV, HDV, and Fibrosis, Including Late-Breaking Data on Hepcludex ® (bulevirtide) in HDV, Demonstrate Gilead’s Commitment to Addressing Unmet Needs for People Living with Liver Disease Studies Evaluate Safety and Efficacy of Hepcludex ® (bulevirtide) in People Living with Chronic HDV FOSTER CITY, Calif. / Nov 03, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD)... Read More

Longer Follow-Up Analyses of Survival Data Showing Curative Intent of Yescarta ® To Be Presented Across Lines of Therapy and Age Groups, Including 65+ Durability of Response and Survival With Tecartus ® in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma Observed in Largest Real World Evidence Studies to Date New Clinical Data From Phase 1 Study of CART-ddBCMA in Patients With... Read More

Kite will gain access to Epic Bio’s gene regulation platform to potentially develop next-generation cancer cell therapies SANTA MONICA & SOUTH SAN FRANCISCO, Calif. / Oct 31, 2023 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform... Read More

The New Report Also Recognized Gilead As the Number One Funder of Organizations Focused on Achieving Health Equity for Key Populations, Including U.S. BIPOC Communities, Transgender Communities and Gay Men FOSTER CITY, Calif. / Oct 24, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report... Read More

Two-Year Resistance Analysis from CAPELLA Pivotal Trial Reinforces Sunlenca as a Person-Centered Option in Combination with an Optimized Background Regimen Latest Research Highlights the Potential Impact of Lenacapavir on the Future of HIV Clinical Care FOSTER CITY, Calif. / Oct 20, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca ® (lenacapavir) as an important... Read More

Three-Year Outcomes from the BICSTaR Study Further Demonstrate the Consistent Efficacy and Safety Profile of Biktarvy, Providing Insights for HIV Clinical Care FOSTER CITY, Calif. / Oct 19, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir... Read More

PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV pre-exposure prophylaxis (PrEP) in France and the United Kingdom FOSTER CITY, Calif. / Oct 18, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will assess... Read More

Partnership combines Gilead’s proven track record and mission to develop transformative therapeutics targeting serious viral diseases, with Assembly Bio’s expertise and focus on antiviral R&D to advance differentiated treatments for herpesviruses, HBV, HDV and beyond Collaboration includes Assembly Bio’s current and future pipeline candidates and incorporates two Gilead herpesvirus programs Assembly Bio to receive $100... Read More

Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy ® in Metastatic Breast Cancers New Data Demonstrate Potential of Trodelvy in Small Cell Lung Cancer, Urothelial Cancer and Head and Neck Cancers Two New Analyses Estimate Treatment Effects of Yescarta Versus Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-cell Lymphoma FOSTER CITY, Calif. & SANTA MONICA, Calif. / Oct 16, 2023 / Business... Read More

Long-Term & Real-World HIV Research Offer Insights into How Treatment with Biktarvy ® and Sunlenca ® May Help Inform the Future of Coordinated, Person-Centered HIV Care Updates on Collaborations with the Global HIV Community Include Initiatives Aimed at Advancing Efforts to End the Epidemic in Eastern Europe and Central Asia FOSTER CITY, Calif. / Oct 16, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today... Read More

FOSTER CITY, Calif. / Oct 12, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2023 financial results and guidance will be released on Tuesday, November 7, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2023 financial results and provide a business update. A live webcast will be... Read More

Latest HIV Treatment Research Reinforces Biktarvy Efficacy Data in a Broad Range of People with HIV and Highlights the Potential Impact of Twice-Yearly Lenacapavir on the Future of HIV Clinical Care Data Reinforces Veklury’s Strong Safety Profile and Continued In Vitro Activity Against New Variants Studies Evaluate Utility of Obeldesivir as a Potential Treatment for COVID-19 FOSTER CITY, Calif. / Oct 03, 2023 / Business Wire... Read More

NACD Directorship 100 Recognizes the Most Influential Corporate Directors and Governance Experts FOSTER CITY, Calif. / Oct 02, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin E. Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the National Association of Corporate Directors (NACD) as part of their 2023 NACD Directorship... Read More

This Positive Opinion Reinforces Veklury’s Strong Safety Profile FOSTER CITY, Calif. / Sep 19, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury ® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European... Read More

Yescarta Achieved a Complete Metabolic Response (CMR) of 71% at 3 Months Versus 12% Expected with Historical Standard of Care Controls Results Published in Nature Medicine SANTA MONICA, Calif. / Sep 18, 2023 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor... Read More

Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studied Results Support Further Investigation of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC FOSTER CITY, Calif. / Sep 10, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02... Read More

FOSTER CITY, Calif. / Sep 07, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1... Read More

This Approval Supports Veklury’s Strong Safety Profile and Makes Veklury the Only Approved COVID-19 Antiviral Treatment Across all Stages of Liver Disease FOSTER CITY, Calif. / Aug 24, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) with no dose adjustments to... Read More

FOSTER CITY, Calif. / Aug 23, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Conference Wednesday, September 6 at 11:00 am ET Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 12 at 11:30 am ET The live webcasts can be accessed at the company’s investors page at... Read More

Enrolled Patients May Continue Receiving Study Medicine Studies in Solid Tumors Unaffected FOSTER CITY, Calif. / Aug 21, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML). The FDA action follows the... Read More

Journal Of Health Care for the Poor and Underserved Supplement Details COMPASS Progress at the Halfway Mark of the Ten-Year Initiative FOSTER CITY, Calif. & NASHVILLE, Tenn. / Aug 18, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one of the nation’s oldest and largest historically Black academic health science centers, today announced the publication of a new supplemental issue of... Read More

Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix’s Tentacles™ Platform Gilead Receives Exclusive Rights to Acquire Novel Therapies From this Collaboration FOSTER CITY, Calif. & SAN DIEGO / Aug 15, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s... Read More

Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion Oncology Sales Increased 38% Year-Over-Year to $728 million Net Income Reflects $525 million Legal Settlement Accrual ($0.32 per share) FOSTER CITY, Calif. / Aug 03, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter... Read More

Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) Metastatic Breast Cancer vs. Physician’s Choice of Chemotherapy Trodelvy Now Indicated in Both Pre-Treated HR+/HER2- Metastatic Breast Cancer and Second-Line Metastatic Triple-Negative Breast Cancer in Europe FOSTER CITY, Calif. / Jul 27, 2023 / Business Wire / Gilead... Read More

Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety and Tolerability Profile of Lenacapavir Analyses Show Oral Bridging Maintains Virologic Suppression When Subcutaneous Lenacapavir Doses are Missed FOSTER CITY, Calif. / Jul 24, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir,... Read More

Cognizant will manage Gilead's global IT infrastructure while leading digital transformation initiatives designed to enhance overall client experience and enable faster time to market for Gilead products. TEANECK, N.J. , July 24, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced an expansion of its relationship with Gilead Sciences (NASDAQ: GILD). Gilead is a leading biopharmaceutical company advancing innovative... Read More

Biktarvy Evaluated in a Diverse Range of People With HIV, Including Pregnant Women and Pediatric Populations – 96-Week Data from ALLIANCE Trial Show Durability of Biktarvy in Adults With HIV and HBV Coinfection – FOSTER CITY, Calif. / Jul 23, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir... Read More

$6 Million USD in Funding Will Help Address Health Disparities Among Indigenous Communities with a Focus on HIV and Viral Hepatitis FOSTER CITY, Calif. / Jul 23, 2023 / Business Wire / Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently... Read More

FOSTER CITY, Calif. / Jul 21, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population. Gilead recommends... Read More

Funding Will Support the Re-Engagement of Diagnosed but Untreated People Living with HCV and HBV in the United States into Care FOSTER CITY, Calif. / Jul 20, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with... Read More

Key Initiatives Highlight the Role of Catalytic Collaboration to Help Advance Health Equity Latest HIV Research and Development Data Drive the Next Wave of Person-Centric Scientific Discovery in Treatment, Prevention and Novel Research Strategies in HIV Cure FOSTER CITY, Calif. / Jul 19, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS... Read More

FOSTER CITY, Calif. / Jul 14, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2023 financial results and provide a business update. A live webcast will be... Read More

Veklury is Now the First Approved Antiviral Treatment for Patients Across all Stages of Renal Disease FOSTER CITY, Calif. / Jul 14, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury ® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.... Read More

Partnership Aims to Accelerate the Development of Dispersible Pediatric HIV Medicines FOSTER CITY, Calif. / Jul 13, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop... Read More

Recommendation Based on the TROPiCS-02 Study Showing Trodelvy Demonstrated Statistically Significant and Clinically Meaningful Overall Survival in Pre-Treated HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) Metastatic Breast Cancer vs. Physician’s Choice of Chemotherapy This Positive Opinion Could Lead to the Second Indication Based on Overall Survival Data for Trodelvy in Metastatic Breast Cancer in Europe FOSTER CITY, Calif. /... Read More

Continued Treatment with Bulevirtide Shows Clinical Benefit and Sustained Viral Decline with Prolonged Treatment in Patients Originally Considered Partial- or Non-Responders FOSTER CITY, Calif. / Jun 23, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex ® (bulevirtide) for the... Read More

Gilead Sciences K.K. is Now Marketing Authorization Holder Kite Cell Therapy Business Unit of Gilead Sciences K.K. will manage the product’s sales and promotion activities Kite’s Southern California Manufacturing Facility Supplying Yescarta for the Japanese Market SANTA MONICA, Calif. / Jun 22, 2023 / Business Wire / Kite Pharma, Inc. , a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in... Read More

6 Oral Presentations and 28 Posters Across HDV, HCV, HBV, NASH and PSC Highlight Progress and Gilead’s Leadership in Addressing Unmet Needs for People Affected by Liver Disease FOSTER CITY, Calif. / Jun 14, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq:GILD) today announced new data to be presented at the European Association for the Study of the Liver (EASL) Congress 2023, June 21-24, 2023. Key findings from more... Read More

License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platform MOUNTAIN VIEW and SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (NASDAQ:GILD). The license agreement will provide AbTherx rights... Read More

In CIBMTR Registry Analysis, Tecartus Also Demonstrates 88% Complete Response Rate and 94% Overall Response Rate in Second-and-Third-Line Treatment Data Highlighted in Oral Presentation at ASCO SANTA MONICA, Calif. / Jun 06, 2023 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus ® (brexucabtagene autoleucel) in patients with relapsed or... Read More

Trodelvy – the First Trop-2-Directed ADC – Delivers a Durable and Clinically Meaningful 3.3 Month Improvement in Median Overall Survival vs. Comparator Chemotherapy in Phase 3 TROPiCS-02 Study Overall Survival Benefit Observed with Trodelvy in Patients with HER2-low (IHC 1+, IHC2+/ISH-) and HER2-IHC0 Status FOSTER CITY, Calif. / Jun 05, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term... Read More

First Treatment in Nearly 30 Years to Show Statistically Significant OS, With a Median Follow-Up of 47.2 Months, for Initial Treatment of R/R LBCL Versus Historical SOC in the Curative Setting Yescarta Results in a 27.4% Reduction in Risk of Death, Corresponding to a 38% Relative Improvement in OS, Despite 57% of Patients Subsequently Receiving Cell Therapy Off Protocol Data Highlighted as Late-Breaking News at ASCO 2023 and... Read More

Eight Presentations on Yescarta ® and Tecartus ® Advance Kite’s Cell Therapy Leadership New Data Highlight Magrolimab’s Potential to Alter the Tumor Microenvironment FOSTER CITY, Calif. & SANTA MONICA, Calif. / Jun 01, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the... Read More

If Granted by the European Commission, Veklury will become the First and Only Authorized Antiviral Treatment Across All Stages of Renal Disease FOSTER CITY, Calif. / May 26, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury ® (remdesivir) in COVID-19... Read More

FOSTER CITY, Calif. / May 25, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: Jefferies Healthcare Conference on Wednesday, June 7 at 11:00am ET The live webcast can be accessed at the company’s investors page at investors.gilead.com. The replay will be available for at least 30 days following the presentation. About Gilead... Read More

Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and Other Solid Tumors Late-Breaking Presentation to Detail Overall Survival Results for Yescarta ® CAR T-Cell Therapy, Showing Statistical Improvement Over Standard of Care for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma... Read More

FOSTER CITY, Calif. / May 16, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30. Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care.... Read More